STXBP1 encodes Munc18-1 (also known as STXBP1), a critical regulator of synaptic vesicle exocytosis. Pathogenic variants in STXBP1 cause STXBP1 encephalopathy, one of the most common genetic causes of early-onset developmental and epileptic encephalopathies (DEEs). The disorder presents with neonatal seizures, a distinctive burst suppression EEG pattern, and profound developmental impairment.
STXBP1 is notable for being one of the most intolerant genes in the human genome (pLI = 1.0), reflecting the severe fitness consequence of loss-of-function variants. It is also associated with non-epileptic neurodevelopmental disorders (intellectual disability, autism, schizophrenia) in patients without seizures[@stxbp1gene2023].
| Property |
Value |
| Gene Symbol |
STXBP1 |
| Chromosomal Location |
9q34.11 |
| Genomic Coordinates |
chr9:127,750,000-127,870,000 (GRCh38) |
| Gene Length |
~120 kb |
| Number of Exons |
20 coding exons |
| Transcript Length |
~2.4 kb coding sequence |
| Protein Length |
594 amino acids |
| Protein Class |
SM (Sec1/Munc18-like) protein; synaptic vesicle fusion regulator |
| Expression |
Brain (neurons throughout); lower expression in other tissues |
| OMIM |
602926 |
| UniProt |
P61764 |
¶ Structure and Function
Munc18-1 is a member of the Sec1/Munc18 (SM) protein family, which are essential for intracellular membrane fusion events. The structure consists of:
- Arch-fold domain: characteristic of SM proteins, formed by three lobes (domains 1-3)
- Syntaxin-1 binding groove: deep cleft where syntaxin-1 binds in a closed conformation
- Phosphorylation sites: regulated by kinases including PKC and CaMKII
Munc18-1 is a master organizer of the synaptic vesicle fusion machinery:
- Munc18-1 binds syntaxin-1, stabilizing it in a closed conformation
- This enables assembly of the SNARE complex (synaptobrevin/VAMP2 on the vesicle, SNAP-25 on the plasma membrane, syntaxin-1 on the plasma membrane)
- Munc18-1 catalyzes the transition of vesicles from a pool to a fusion-competent "primed" state
- Munc18-1 acts as a chaperone for syntaxin-1 folding and trafficking
- It holds syntaxin-1 in the proper conformation for SNARE complex formation
- Without Munc18-1, syntaxin-1 fails to properly incorporate into SNARE complexes
- Munc18-1 interacts with synaptotagmin-1 (the calcium sensor for vesicle fusion)
- It couples the calcium signal to the fusion machinery
- Munc18-1 may help position vesicles for optimal calcium-triggered fusion
- PKC phosphorylation of Munc18-1 modulates its interactions
- CaMKII phosphorylation affects vesicle release probability
- Activity-dependent regulation of Munc18-1 contributes to synaptic plasticity
¶ Cellular and Network Consequences
Loss of Munc18-1 disrupts both inhibitory (GABAergic) and excitatory (glutamatergic) transmission:
- Reduced vesicle priming → fewer fusion-ready vesicles
- Impaired SNARE complex function → inefficient fusion events
- Disrupted calcium coupling → desynchronized release
- Network hyperexcitability → seizures
- Impaired plasticity → developmental dysfunction
| Disorder |
Variant Type |
Inheritance |
Key Features |
| STXBP1 encephalopathy (with epilepsy) |
Missense, nonsense, truncating, splice |
De novo (majority) |
Neonatal onset, burst suppression, severe ID, movement disorder |
| Non-syndromic intellectual disability |
Missense, truncating |
De novo |
ID, no seizures; may be non-syndromic presentation |
| Autism spectrum disorder |
Missense, variants |
De novo, inherited |
ASD, ID; often without seizures |
| Schizophrenia |
Missense, variants |
Inherited (rare) |
SCZ, ID, seizures |
- Missense variants in domain 1 (S1-S3): often severe
- Truncating variants: severe; NMD and haploinsufficiency
- Splice variants: variable, often severe
- Mosaic variants (parental): milder phenotype possible
STXBP1 is a high-priority gene therapy target:
- Haploinsufficiency mechanism (50% expression likely beneficial)
- Gene size (~2kb coding) easily fits in AAV
- Early intervention before developmental regression critical
See clinical trial page for STXBP1 encephalopathy and therapeutics hub page.
- Timing: burst suppression EEG in the first months suggests early intervention is critical
- Cell-type specificity: achieving expression in relevant neuronal populations
- Endpoint selection: seizure frequency measurable, but developmental endpoints challenging
¶ Research and Open Questions
- Why burst suppression? — what cellular mechanism produces this pathognomonic EEG pattern?
- Why this specific cell type? — understanding selectivity for interneurons vs. excitatory neurons
- Optimal therapeutic window — when does intervention need to occur to prevent irreversible damage?
- Non-epileptic presentations — why do some variants cause ID/ASD without seizures?
- Biomarkers — what can serve as early pharmacodynamic markers for trials?
- [@stxbp1gene2023] STXBP1: from synaptic function to neurodevelopmental disorders